健常人および糖尿病患者の水晶体計画的嚢外摘出術におけるFlurbiprofen点眼薬の瞳孔径に及ぼす影響

Prevention of miosis by topical flurbiprofen during extracapsular cataract surgery in diabetic and nondiabetic subjects

　糖尿病を合併した白内障，および合併しない白内障の水晶体計画的嚢外摘出術32眼を対象として，Flurbiprofen （FP）点眼薬の術中，術後の縮瞳抑制効果について検討を加えた．その結果，FP点眼液は糖尿病を合併しない症例については後中の縮瞳反応を有意に抑制した．しかし，糖尿病を合併した症例については縮瞳抑制効果は認められなかった．

We evaluated the effect of topical flurbiprofen, a potent prostaglandin synthetase inhibitor, in suppress-ing miosis when applied prior to planned extracapsular cataract surgery. A series of 16 cataractous eyes each with and without cataract served as material in the present study.

One drop of 0.1% flurbiprofen or placebo was instilled 3, 2, 1 and 1/2 hours before surgery. It was also instilled 3 times daily for 7 postoperative days. The miosis-suppression effect was evaluated by the response parameter, (Dmax-D) /Dmax-Dmin), which was calcu-lated from the pupil diameter. D stands for pupil size after start of surgery. Dmax, the maximum pupil diame-ter , was determined after instillation of mydriatics prior to surgery. Dmin, the minimum pupil diameter, was assumed as 1 mm.

In non-diabetic subjects, the response parameter at the end stage of anterior capsulotomy was 0.036+0.055 in flurbiprofen-treated group and 0.156+0.091 in the placebo group. At the end of surgery, the parameter was 0.340+0.104 in the flurbiprofen group and 0.450ｱ0.089 in the control group.Thus, flurbiprofen tended to sup-press pupil contriction during surgery when compared with placebo (p< 0.1).

In diabetic subjects, no difference was noted in pupil response parameter between flurbiprofen and placebo groups.

Rinsho Ganka (Jpn J Clin Ophthalmol) 40(6) : 621-624, 1986